Importantly, we here show that SLAMF7 continues to be expressed in heavily pretreated MM patients, indicating that treatment with IMiDs, proteasome inhibitors or CD38 antibodies does not impact SLAMF7 expression on MM cells. The gene discussed is CD38; the disease is Miyoshi myopathy.